SSTR2 expression in TET, specifically lymphoepithelial carcinomas, squamous cell carcinomas, atypical carcinoid tumors, and small cell carcinomas may be a biomarker to identify patients who may respond to octreotide therapy. The gene discussed is SSTR2; the disease is atypical carcinoid tumor.